KDM1A inhibition by HCI-2509 downregulates MYC expression in prostate cancer cells, suggesting that it may act as a promising therapeutic in castration- and docetaxel-resistant prostate cancer [157]. The gene discussed is KDM1A; the disease is prostate carcinoma.